Brazil Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Brazil Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Brazil nuclear imaging market was valued at USD 159.79 million in 2021 and is projected to register a CAGR of 3.72% during the forecast period (2022-2027).

The pandemic had an adverse effect on the country. Cancer patients were particularly affected by these activities since the length of time needed for screens, diagnoses, and treatment beginning had a negative impact on outcomes. Brazil's Ministry of Health (MoH) established an Emergency Operations Centre (COE) in January 2020 to respond to potentially affected cases, educate medical personnel nationwide, and offer tests and clinical practice recommendations. The Oswald Cruz Foundation (Fiocruz), the Pan American Health Organization (PAHO), and Anvisa (the Brazilian Health Regulatory Agency—Agencia Nacional de Vigilancia Sanitaria) made up the COE (PAHO). The COVID-19 scenario has also given market participants numerous possibilities to fortify their positions and acquire a competitive edge through strategic partnerships, mergers, or acquisitions. For instance, in June 2021, Isotope JSC, a division of Rusatom Healthcare JSC, Rosatom's radiation technologies integrator, agreed to a five-year supply agreement for lutetium-177 and actinium-225, the two most promising medical isotopes in radiopharma, with Brazil's Nuclear and Energy Research Institute. The agreement enhances ROSATOM's position as the main provider of radioisotopes to the markets in Latin America. Thus, the market was adversely affected by the pandemic.

Brazil is expected to contribute to the market's expansion due to the increased prevalence of diseases, technical advancements, the introduction of novel radiopharmaceuticals for diagnosis, and the development of molecular imaging. Additionally, almost 10% of all hospital admissions in Brazil are related to cardiovascular disorders, according to a report published in June 2020 with the title "Characterization of Brazilian hospital admissions owing to cardiovascular diseases: a longitudinal study." It also came to the conclusion that a significant portion of hospital admissions related to cardiovascular diseases are caused by stroke (11.4%), heart failure (21.3%), and other ischemic heart disorders (13.3%). The SPECT technique, which employs thallium-201 (201Tl), is preferable for the evaluation of cardiac perfusion and the integrity of the cellular membrane, according to the "Update of the Brazilian Guideline on Nuclear Cardiology - 2020" published in SciELO Brasil in February 2020. Such recommendations and guidelines are anticipated to accelerate market expansion. Eckert & Ziegler began shipping Technetium-99 generators to Brazil in August 2021. The Brazilian health agency ANVISA recently granted a license to the subsidiary Eckert & Ziegler Brasil Comercial Ltda., making it the first and only private company authorized to import and sell technetium generators. The first clients include two renowned hospitals in the greater Sao Paulo region. . Around 500 hospitals and clinics in the nation receive their medical supplies and radioisotopes from Eckert & Ziegler. Thus, the abovementioned factors are expected to increase market growth.

However, the lack of proper reimbursement and stringent regulatory approval procedures, and the high cost of equipment, are expected to hinder the market growth in Brazil.

Key Market TrendsOncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Due to the rising prevalence of diseases, technological improvements, the launch of novel radiopharmaceuticals for diagnosis, and the advancement of molecular imaging, Brazil is anticipated to account for the market's growth. In addition, the prevalence of chronic diseases is rising, as is the usage of PET and SPECT scans. The Global Cancer Observatory forecasts that Brazil will see 259,949 cancer deaths and an estimated 592,212 new cancer cases in 2020. The demand for nuclear imaging is anticipated to rise as a result of increased launches by major market participants in the sector, a growth in regulatory body approvals, as well as numerous agreements and collaborations across the nation. For instance, Grupo RPH and gate-Startup OncoBeta GmbH sign a contract in September 2020 for the sale, distribution, and treatment of rhenium-induced skin cancer in Brazil. In the article "Evaluation of the Clinical Use of PET/CT with 68 Ga-PSMA for the Assessment of Biochemical Recurrence of Low or Intermediate-Risk Prostate Cancer," published in 2021, André Marcondes Braga Ribeiro of the A.C. Camargo Cancer Center in So Paulo stated that 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography is useful for the Assessment of Biochemical Recur. Thus, due to the abovementioned factros the market is expected to grow in the future.

Competitive Landscape

Brazil nuclear imaging market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are GE Healthcare, Siemens Healthineers AG, Canon Inc. (Canon Medical Systems Corporation), Grupo RPH, and Koninklijke Philips NV among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.